脂蛋白在心血管疾病和新兴治疗策略中的作用
Rami A Al-Horani1,2, Alexandra C Selico-Dunn3, Emily Lauren Schenk Smith3
1Division of Basic Pharmaceutical Sciences, College of Pharmacy, Xavier University of Louisiana, New Orleans, LA, 70125, USA. ralhoran@xula.edu.
Cardiovascular drugs and therapy
|November 20, 2025
概括
脂蛋白 (Lp) 是动脉样硬化心血管疾病的一个关键遗传风险因素. 新兴疗法在降低Lp (a) 水平和减轻心血管风险方面表现有前途.
科学领域:
- 心脏病学和遗传学
- 分子生物学和生物化学 分子生物学和生物化学
背景情况:
- 脂蛋白 (Lp) 是动脉样硬化心血管疾病 (ASCVD) 的独立,基因决定的风险因素.
- 了解Lp(a) 在ASCVD,大动脉狭窄和外周动脉疾病中的作用对于风险分层至关重要.
研究的目的:
- 审查Lp的结构,病理生理学和流行病学.
- 检查Lp (a) 对心血管风险的贡献以及新兴疗法的影响.
主要方法:
- 综合了关于Lp(a) 的生物特征和疾病机制的已发表证据.
- 评估的临床试验数据Lp(a) 向疗法.
主要成果:
- Lp (a) 通过益风险,益炎症和前血栓机制促进剩余心血管风险.
- 新兴疗法 (反感性寡核酸,siRNAs,小分子,基因编辑) 在降低Lp(a) 水平方面显示出有希望的疗效和安全性.
- 这些疗法有可能显著改变心血管预防策略.
结论:
- 随着新型治疗方法的发展,Lp (a) 正在成为个性化心血管护理的核心因素.
- 增加Lp (a) 测试对于风险分层和治疗决策至关重要.
相关概念视频
Atherosclerosis III: Management
301
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
301
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
Atherosclerosis I: Introduction
835
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
835
Coronary Artery Disease IV: Preventive Measures
577
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
577
Peripheral Artery Disease III: Interprofessional Care
229
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
229
Coronary Artery Disease I: Introduction
857
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
857


